Lyndra is developing several product candidates internally as well as partnering with a select number of leading biopharmaceutical companies to develop ultra-long acting formulations of proprietary, small molecule therapies.

The technology offers significant benefits via product differentiation in competitive markets, lifecycle extensions to innovative products as well convenient alternatives to long-acting injectables.

The company’s internal development formulations are compounds for neuropsychology indications. All product candidates are once-weekly formulations in pre-clinical development.

For partnership inquiries please contact us here.